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ABSTRACT
The predictive value of circulating microRNAs (miRNAs) in hepatitis B virus 
(HBV)-related hepatocellular carcinoma (HCC) has been demonstrated in retrospective 
studies, but it has rarely been tested in prospective studies. In a cohort of 373 cancer-
free HBV patients with a median follow-up of 4.5 years, we measured the expression 
of 24 retrospectively identified HCC-related miRNAs in baseline serum samples. When 
we analyzed the prospective associations of miRNA expression with HCC risk using 
the Cox proportional hazards model, we found that 15 of the 24 miRNAs exhibited a 
significant association with HCC risk. In particular, 7 miRNAs (miR-122, miR-99a, miR-
331, miR-125b, miR-23b, miR-92a, and miR-26a) were associated with an increased 
risk, and 8 miRNAs (miR-652, miR-23a, miR-27a, miR-34a, miR-145, miR-10a, miR-
150, and let-7f) were associated with a decreased risk. Compared to HBV patients with 
a low miRNA-based risk score, those with a high miRNA-based risk score exhibited 
a significantly elevated HCC risk in both univariate (hazard ratio [HR] 6.56, 95% 
confidence interval [CI] 2.74-15.70) and multivariate (HR 3.57, 95% CI 1.34-9.48) 
analyses. The risk score significantly increased the HCC prediction performance of 
alpha-fetoprotein (concordance index increased from 0.68 to 0.82, P < 0.0001). 
In silico analyses indicated that the genes targeted by the 15 miRNAs are mainly 
enriched in the transforming growth factor-beta signaling pathway. Collectively, these 
results provide prospective evidence that circulating miRNAs serve as non-invasive 
markers for risk prediction of HCC in HBV patients.
INTRODUCTION
Hepatocellular carcinoma (HCC), the major 
histological subtype of primary liver cancers, is the fifth 
most prevalent malignancy and the third leading cause 
of cancer death [1, 2]. Chronic hepatitis B virus (HBV) 
infection is the most prevalent risk factor for HCC, 
accounting for more than 50% of HCC worldwide [3, 4]. 
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HBV-related HCC has grown significantly in the United 
States during the past several decades, largely due to the 
influx of immigrants from HBV-endemic regions [5]. 
A recent report indicated that among the more than 40 
million Americans born outside of the United States, 1.5 
million had chronic HBV infection [5]. More than 60% of 
these HBV patients are relatively young and their risks of 
developing HCC increase significantly as they age [6]. The 
overall 5-year survival rate of HCC is extremely low due 
to limited therapeutic options [7], but survival is markedly 
improved in patients diagnosed and treated early [2]. 
These facts highlight the importance of identifying HBV 
patients at high-risk of HCC for targeted prevention and 
management.
MicroRNAs (miRNAs) play important roles in 
a wide range of biological processes [8–10]. MiRNAs 
could act as oncogenes or tumor suppressors by targeting 
and silencing mRNAs involved in carcinogenesis, and 
have been significantly implicated in the initiation and 
progression of various human cancers [11, 12]. HCC 
tumors exhibited different miRNA expression patterns 
compared to normal healthy liver or non-neoplastic 
peritumoral tissue, suggesting the potential of using 
miRNAs as tissue-based HCC biomarkers [13–16]. 
Recently, circulating miRNAs in serum or plasma have 
shown promise as risk prediction and early detection 
markers for HCC because of their stability in circulation, 
non-invasive procurement, and ease of detection [13, 17, 
18]. Li et al. [19] identified 13 serum miRNAs that could 
distinguish HBV-positive HCC cases from healthy controls 
and cancer-free HBV cases. Zhou et al. [20] reported 
a plasma-based 7-miRNA panel with high diagnostic 
accuracy for HCC. The performance of this panel was 
independent of disease status and exhibited promising 
clinical value in diagnosing early-stage HBV-HCC 
patients [20]. Nevertheless, the vast majority of published 
studies measured circulating miRNAs from patients 
already diagnosed with HCC, especially late-stage HCC. 
Thus, whether the alterations of these identified miRNAs 
are the cause or consequence of hepatocarcinogenesis 
remains undetermined.
Mechanistic studies using animal model or liver 
tissue have suggested that aberrant expressions of certain 
miRNAs precede HCC development [21, 22]. Two recent 
multi-stage studies validated some retrospectively-
identified circulating miRNAs using prospectively 
collected samples [23, 24]; however despite the promising 
findings, neither study reported an identical miRNA 
signature, even though both studies were conducted in 
Chinese HBV-HCC patients. To learn more about miRNA 
expression in HCC development, we tested the hypothesis 
that the expression profile of serum miRNAs alone, or 
combined with alpha-fetoproteins (AFP, a traditional HCC 
marker commonly used in current clinical settings), can 
prospectively predict HCC development in HBV patients. 
Our study took advantage of serum samples that were 
prospectively collected many years before HCC diagnosis 
in a unique population of Asian Americans with chronic 
HBV infection.
RESULTS
Characteristics of the study population
There were 379 cancer-free HBV patients who met 
the 1-year exclusion criteria of being followed for at least 
1 year, during which time HCC did not develop. These 
exclusion criteria were used to minimize the confounding 
effects of undiagnosed HCC patients at study entry. After 
excluding 6 patients with a more than 50% failure rate 
in the detection of 24 miRNAs expression, 373 patients 
with a median age of 43.2 years (interquartile range [IQR] 
36.6-50.8 years) were included in the primary prospective 
cohort. During a median follow-up of 4.5 years (IQR 
2.4-7.8 years), 40 (10.7%) of the 373 patients developed 
HCC. The median time to HCC diagnosis was 4.0 years 
(IQR 2.0-9.6 years). Compared to the HBV patients 
who remained cancer-free during follow up, those who 
developed HCC were older (P < 0.0001), more likely to be 
ever-smokers (P = 0.0301), cirrhotic (P < 0.0001), and had 
high AFP levels (P = 0.0005). The demographics variables 
of the study subjects appear in Table 1.
Prospective association of the expression levels of 
baseline serum miRNAs with HCC risk
Among the 24 tested miRNAs, miR-98 and miR-
338-3p were excluded from further analyses due to ≥ 50% 
missing values in all patients. Significance Analysis of 
Microarrays (SAM) analysis identified 15 differentially 
expressed miRNAs that were significantly associated 
with HCC risk, including 7 miRNAs (miR-122, miR-99a, 
miR-331, miR-125b, miR-23b, miR-92a, and miR-26a) 
for which an elevated expression was associated with an 
increased risk (risk miRNAs), and 8 miRNAs (miR-652, 
miR-23a, miR-27a, miR-34a, miR-145, miR-10a, miR-
150, and let-7f) for which an elevated expression was 
associated with a decreased risk (protective miRNAs) 
(Table 2).
A miRNA-based risk score
To assess these significant miRNAs as a panel, a risk 
score based on the linear combination of the expression 
levels of the 15 miRNAs, weighted by the SAM d-value 
(Table 2), was calculated for each patient. Figure 1 
delineates the distributions of the risk scores (Figure 1A), 
follow-up time (Figure 1B), and serum miRNA expression 
levels (Figure 1C) of the 373 HBV patients. Each 
patient was then assigned to either a high- or a low-risk 
group according to the median cutoff of the risk scores. 
Compared to the patients with low-risk scores, those with 
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high-risk scores tended to have more risk miRNAs and 
less protective miRNAs, and were more likely to develop 
HCC during follow-up (Figure 1).
Compared to the HBV patients with low-risk scores, 
those with high-risk scores had a 6.56-fold increased risk 
for HCC (95% confidence interval [CI] 2.74-15.70) and 
exhibited a significantly higher cumulative incidence of 
HCC during follow-up (Plogrank = 1.23×10
-6, Figure 2A). 
After adjustment for age, gender, smoking status, drinking 
status, family history of cancer, cirrhosis status, and AFP 
values, the association of the risk score with HCC risk 
remained significant (hazard ratio [HR] 3.57, 95% CI 
1.34-9.48).
When we further restricted the prospective analyses 
to a sub-cohort of patients with a 2-year exclusion 
window (297 HBV patients, including 30 patients who 
developed HCC during follow-up), the result of the 
sub-cohort analysis (Plogrank = 5.00×10
-5, Figure 2B) was 
consistent with that of the primary cohort (Figure 2A). 
The association between risk scores and HCC risk in the 
sub-cohort subjects was statistically significant in both 
univariate (HR 5.88, 95% CI 2.24-15.45) and multivariate 
analyses (HR 2.96, 95% CI 1.05-8.32).
Prediction performance of the 15-miRNA risk 
scores and AFP
We then assessed the prediction performance of the 
15-miRNA risk scores and AFP using concordance index 
(C-index) [25]. In the primary prospective cohort with the 
Table 1: Characteristics of the study population
Variables Total subjects (N=373, 100%)
HBV patients who 
did not develop HCC 
(N=333, 89.28%)




Age     
 ≤ Median 172 (46.11) 166 (49.85) 6 (15.00) <0.0001
 > Median 201 (53.89) 167 (50.15) 34 (85.00)  
Gender     
 Female 115 (30.83) 108 (32.43) 7 (17.50) 0.0533
 Male 258 (69.17) 225 (67.57) 33 (82.50)  
Smoking status     
 Never 244 (65.42) 224 (67.27) 20 (50.00) 0.0301
 Ever 129 (34.58) 109 (32.73) 20 (50.00)  
Drinking status     
 Never 220 (58.98) 198 (59.46) 22 (55.00) 0.5880
 Ever 153 (41.02) 135 (40.54) 18 (45.00)  
Family history of cancer
 No 240 (64.34) 217 (65.17) 23 (57.50) 0.3389
 Yes 133 (35.66) 116 (34.83) 17 (42.50)  
Cirrhosis     
 No 244 (65.42) 240 (72.07) 4 (10.00) <0.0001
 Yes 129 (34.58) 93 (27.93) 36 (90.00)  
AFP     
 ≤ Median 181 (48.53) 172 (51.65) 9 (22.50) 0.0005
 > Median 192 (51.47) 161 (48.35) 31 (77.50)  
HBV: hepatitis B virus; HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein.
*The distributions of host characteristics in HBV patients who developed HCC and who did not were compared by chi-
square test.
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Table 2: Differentially expressed miRNAs in HBV-HCC patients
ID d-value Numerator(r) Denominator(s+s0) q-value(%)
miR-122 2.8584 7.0516 2.4669 0
miR-99a 1.8061 2.2889 1.2673 0
miR-331 1.6990 1.7507 1.0305 0
miR-125b 1.6342 1.8521 1.1333 0
miR-23b 1.5654 1.4624 0.9342 0
miR-92a 1.2883 1.3291 1.0317 0
miR-26a 1.0043 1.1242 1.1193 3.63
miR-652 -2.4714 -4.2271 1.7104 0
miR-23a -2.3286 -3.5700 1.5331 0
miR-27a -2.2951 -3.2686 1.4242 0
miR-34a -1.6421 -2.2733 1.3844 0
miR-145 -1.5791 -2.9245 1.8520 0
miR-10a -1.5007 -2.2113 1.4735 0
miR-150 -1.1032 -1.9654 1.7815 1.95
let-7f -1.0657 -1.0167 0.9540 1.95
HBV: hepatitis B virus; HCC: hepatocellular carcinoma.
1-year exclusion window, the C-index for the 15-miRNA 
risk scores was 0.74 (95% CI 0.66-0.82), based on a 5-year 
prediction (Table 3). A statistically significant increase in 
C-index was observed when 15-miRNA risk scores were 
incorporated into the model including AFP values only 
(0.68 for AFP only model vs. 0.82 for the model including 
miRNA risk scores plus AFP values, P < 0.0001). The 
sub-cohort analysis of patients with the 2-year exclusion 
window showed very similar results (Table 3).
In silico analyses for potential functions of the 
genes regulated by the 15 significant miRNAs
A total of 540 potential target genes were identified 
in the four algorithms of TargetScan, miRanda, miRDB, 
and PicTar. The Ingenuity Pathway Analysis (IPA) 
analysis suggested that cancer (P = 9.88×10-16-1.99×10-4) 
and gastrointestinal disease (P = 4.97×10-12-1.27×10-4) 
ranked as the top two diseases that were associated 
with these target genes. The top five enriched canonical 
pathways are shown in Figure 3A. The transforming 
growth factor-beta (TGF-β) signaling pathway was the 
most significant pathway regulated by these genes (P = 
5.14×10-8). Molecular and cellular functions related to 
these genes include cell growth and proliferation, cellular 
development, gene expression, cell morphology, and cell 
death and survival. Moreover, the top network identified 
with this method was defined as “Cell-To-Cell Signaling 
and Interaction, Tissue Development, Nervous System 
Development and Function” (Figure 3B). Functional 
descriptors assigned by the Ingenuity Knowledge Database 
to the molecules in the top network include organismal 
death, cancer, cell death, and apoptosis.
DISCUSSION
Aberrant expression of circulating miRNAs has 
been observed in HCC patients in retrospective studies, 
but it has rarely been tested in a prospective setting. In this 
study we demonstrated that a signature of 15 circulating 
miRNAs could prospectively predict HCC development in 
HBV patients, suggesting that these circulating miRNAs 
may be candidates for next-step validations as promising 
HCC risk predictors.
Recent studies identified differentially expressed 
circulating miRNAs in HCC patients that could separate 
HCC patients from cancer-free HBV patients [19, 20, 23, 
24, 26, 27]. However, most studies adopted a retrospective 
design that used blood samples collected at or after HCC 
diagnosis. Therefore, their conclusions were significantly 
constrained by the reverse-causation limitation that is 
inherent in most retrospective studies. Our prospective 
analyses with a 1-year exclusion window circumvented the 
reverse-causation limitation. Using blood samples collected 
before HCC diagnosis, we demonstrated the prospective 
predictive value of a panel of circulating miRNAs, 
including miR-92a and miR-145, the two miRNAs which 
were recently validated in two Chinese cohorts [23, 24]. To 
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minimize the confounding effect of patients who actually 
had HCC but were not diagnosed at study entry, we further 
restricted the analyses to a sub-cohort of patients with a 
2-year exclusion window. This more stringent analysis 
yielded very similar results, further substantiating the 
prospective value of our circulating miRNA signature.
The differential miRNAs expressions between HBV 
and HCC patients in our patient cohort are consistent 
with previous functional studies. MiR-92a is commonly 
considered an onco-miRNAs because it up-regulates 
angiogenesis and increases cell proliferation [28]. 
Several studies have detected significantly high levels of 
circulating miR-92a in HBV-related HCC patients [19, 
24, 29], consistent with our findings. Let-7a, the most 
important member of the let-7 tumor suppressor family, 
inhibits HCC cell proliferation via down-regulating signal 
transducer and activator of transcription 3 and c-myc, and 
up-regulating p16INK4A [30, 31]. In line with our findings, a 
Figure 1: Risk score analyses of 373 HBV patients. A. Risk score distribution, X-axis represents patients, and each dot in the blue 
line represents the risk score for each patient; B. The status of HBV patients with/without hepatocellular carcinoma (HCC) and follow-up 
time, red triangles indicate HCC patients, and black dots indicate cancer-free HBV patients; C. Color-gram of miRNA expression profiles 
of HBV patients, rows represent miRNAs, and columns represent patients.
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recent study [19] showed that 3 serum miRNAs, including 
let-7f, could separate HBV-HCC cases from controls. 
MiR-122, the most abundant liver-specific miRNA, is 
considered a suppressor of cell proliferation and malignant 
transformation of hepatocytes with remarkable tumor 
inhibition activity [32–34]. Interestingly, although down-
regulation of miR-122 was frequently reported in the HCC 
tumor tissues [2, 34, 35], Qi et al. [36] showed that miR-
122 in serum was elevated in HCC patients and markedly 
reduced in post-operative serum samples, which is 
consistent with the observation in our study. The paradox 
of miR-122 expression in blood and tissues may be 
attributed to the increased release of miRNAs from tumor 
cells into blood [13], and needs further investigation.
AFP is currently the only non-invasive circulating 
marker for HCC screening, but it has limited sensitivity 
and specificity [13, 37]. Identification of novel non-
invasive markers that complement AFP is important 
to the early detection of HCC. Our results showed that 
serum miRNAs significantly improved the prediction 
performance of AFP (Table 3). During a 5-year follow-
up period, miRNA risk scores identified 15 of 16 patients 
(94%) who were misclassified as cancer-free patients by 
AFP, significantly improving sensitivity (data not shown). 
In contrast, among the 57 patients who were misclassified 
as having HCC due to high AFP values, miRNA risk scores 
correctly re-classified 33 (58%), reducing false positive 
findings. Nonetheless, although miRNA risk scores 
significantly increased the sensitivity of HCC prediction, 
they did not significantly improve specificity, as evidenced 
by the large number of cancer-free HBV patients with high 
risk scores (Figure 1B). This was consistent with findings 
from recent prospective studies that reported miRNA 
signatures with high sensitivity and low specificity [23, 
24]. Efforts are needed to identify additional miRNAs 
in order to further reduce false positives and increase 
specificity in HCC prediction.
Whether miRNAs behave as oncogenes or tumor 
suppressor genes depends on the cellular functions 
of their target genes [13, 38]. We conducted in silico 
analyses and found that the TGF-β signaling pathway is at 
the top of the list of canonical pathways regulated by the 
significant miRNAs identified in our study. TGF-β protein 
modulates a broad spectrum of cellular processes [39], has 
dual regulatory functions in the immune system, and is 
activated in response to viral infection, such as HBV [40]. 
Indeed, an initial step triggering HCC in HBV-infected 
patients is epithelial-to-mesenchymal transformation, 
which is modulated by TGF-β [41]. The inhibition of 
TGF-β is directed against some of the most fundamental 
pathological events which lead to chronic liver disease 
and subsequently to HCC [42]. Echoing these reports, our 
data highlighted the importance of the TGF-β signaling 
pathway in HCC initiation, suggesting a potential link 
between aberrant miRNA expression, TGF-β, and HCC 
development in HBV patients. Functional studies are 
warranted to further elucidate the biological mechanisms 
underlying these observations.
Our study has several strengths. It is among the 
very few studies to analyze circulating miRNAs in 
HCC development using a prospective design, which 
allows it to bypass the reverse-causation limitation that 
Figure 2: 15-miRNA risk scores associated with the risk of HBV-related hepatocellular carcinoma (HCC). The cumulative 
incidence of HCC in HBV patients at a high (red line) or a low (blue line) risk group based on the median cutoff of risk scores were plotted 
using the Nelson-Aalen method in patients with a A. 1-year or B. 2-year exclusion window.
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is inherent in retrospective studies. The vast majority of 
our patients were infected with HBV at birth or childhood, 
making our population an ideal cohort to study the long-
term risk of HCC development associated with HBV 
infection. The study was restricted to patients of Korean 
ancestry to eliminate the potential confounding effects of 
patient ethnicity. There are also limitations in our study. 
Firstly, rather than conducting a comprehensive genome-
wide profiling using miRNA microarray or small RNA 
sequencing, we used a candidate approach to select 
promising miRNAs based on the findings of previous 
studies. Although cost-effective, this approach might 
miss novel important miRNAs not identified in previous 
studies. This limitation may account for the low specificity 
of the miRNA risk score observed in our study, and could 
be remedied in the future by adding more significant 
miRNAs to the score. Secondly, given the potential 
interindividual, intraindividual, analytic, and preanalytic 
variations that may affect circulating miRNA levles 
[43], detecting miRNA expression using blood samples 
collected at only one time point, although routinely used 
in population studies [24, 44, 45], may introduce sample 
selection bias. Thirdly, we used cancer-free HBV patients, 
instead of HBV-free healthy subjects, as controls in this 
study, which may limit the generalization of our findings. 
Fourthly, malignant transformation induced by chronic 
HBV infection is a multistage pathogenic process and 
involves multiple risk predictors [37]. Several variables 
Table 3: Discriminatory accuracy for predicting the development of HCC within 5 years
5-year risk prediction C-index (95% CI)
1-year exclusion window  
 miRNA risk scores only 0.74 (0.66-0.82)
 AFP values only 0.68 (0.58-0.78)
 miRNA risk scores plus AFP values 0.82 (0.74-0.89)
2-year exclusion window  
 miRNA risk scores only 0.75 (0.66-0.83)
 AFP values only 0.66 (0.53-0.79)
 miRNA risk scores plus AFP values 0.83 (0.76-0.90)
HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein; CI: confidence interval; C-index: concordance index.
Figure 3: In silico analyses for potential functions of the genes regulated by the 15 significant miRNAs. A. The top five 
enriched canonical pathways implicated in miRNA-mediated HCC development and B. the top-ranked network formed by predicted 
miRNA target genes and functionally related molecules were identified.
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usually collected in population studies were not recorded 
in our medical charts, such as dietary intake, occupational 
exposure, physical activity, and socioeconomic status. 
However, the majority of host factors that are consistently 
associated with HBV progression and HCC risk were 
available from our charts. Finally, despite the many 
strengths and unique prospective nature, our study has a 
relatively small number of patients who developed HCC 
and thus our findings need to be validated using larger and 
independent prospective patients cohorts.
In conclusion, using a prospective approach to 
analyze circulating miRNAs in baseline serum samples 
collected at least 1 year before HCC diagnosis, we 
identified aberrant serum miRNA expressions that were 
associated with HBV-related HCC risk. Our findings 
suggested that circulating miRNAs may serve as non-




This prospective study was based on an existing 
and ongoing clinic-based cohort established in 1988 
at the Liver Disease Prevention Center of the Thomas 
Jefferson University Hospital. Patients who visited the 
Center for treatment of liver-related diseases, including 
HCC, were consecutively enrolled [6]. There were no 
restrictions on age, gender, and disease etiology in patient 
recruitment. Approximately 90% of the patients had 
HBV infection, and over 90% were of Korean ancestry. 
Our study only included cancer-free HBV patients and 
HBV-related HCC patients of Korean ancestry in order 
to eliminate the confounding effects of population 
stratification and disease etiology. The patients included 
in the primary prospective cohort also met the following 
additional criteria: 1) had a 1-year exclusion window; 
2) had baseline blood samples collected at least 1 year 
before the diagnosis of HCC; 3) had available major 
demographic and clinical data. This study was approved 
by the Institutional Review Board at Thomas Jefferson 
University.
Epidemiological and clinical data collection
Demographic and clinical data were collected for 
each patient from medical chart review and consultation 
with the treating physicians. Demographic variables 
included age, gender, ethnicity, smoking status, drinking 
status, cirrhosis, and family history of cancer. Ever 
smokers and drinkers were defined as described previously 
[6]. Liver cirrhosis and HCC were diagnosed by the 
combination of clinical diagnosis and imaging techniques 
(ultrasound, computed tomography, or magnetic resonance 
imaging), complemented by blood markers such as AFP. 
Blood samples were drawn from each patient when taking 
clinical laboratory testing.
Total RNA isolation
Total RNA was isolated from 400 μL serum samples 
using the miRNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. To allow for normalization of 
sample-to-sample variation in RNA isolation, synthetic 
C. elegans miRNAs cel-miR-39 and cel-miR-54 (RNA 
oligonucleotides synthesized by Qiagen) were added to 
each sample [17, 34, 46]. The concentration of total small 
RNA molecules was quantified by a Qubit Fluorometer 
(Life Technologies). The integrity and size distribution of 
the total small RNAs were analyzed using the small RNA 
chip on a Bioanalyzer 2100 (Agilent).
Selection of miRNAs to be tested in this study
We conducted a comprehensive literature review 
to select candidate miRNAs to be included in this study. 
Literatures were identified by searching PubMed using 
keywords “microRNA”, “serum”, “plasma, “circulating”, 
and “HCC” to identify studies that reported miRNAs 
related to the risk prediction and early detection of 
HCC. Additional studies were identified and supplied 
by checking the references of these original studies and 
related review articles. We excluded the publications that 
were 1) unrelated to miRNA expression, 2) unrelated 
to HCC risk, 3) related to HCV-HCC only, 4) related 
to miRNA expression in liver tissues only. Finally, we 
identified eight references (by 2014) on serum or plasma 
miRNA profiling in HBV/HCC patients [13, 19, 20, 34, 
36, 37, 47, 48]. We then selected candidate miRNAs 
following the criteria: 1) miRNAs were expressed in 
human serum or plasma samples; and 2) the expression 
levels of miRNAs were significantly different between 
cancer-free HBV patients and HBV-related HCC patients. 
We selected a total of 24 miRNAs (let-7a, let-7c, let-7f, 
miR-10a, miR-21, miR-23a, miR-23b, miR-26a, miR-
27a, miR-34a, miR-92a, miR-98, miR-99a, miR-122, 
miR-125b, miR-145, miR-150, miR-223, miR-331, miR-
342-3p, miR-375, miR-338-3p, miR-423-3p, and miR-
652) to determine their expression levels and explore their 
prospective association with HCC risk.
Determination of miRNA expression levels
The expression levels of selected miRNAs were 
quantitated using quantitative real-time PCR (qRT-PCR) 
assay as described previously [17, 49]. Briefly, purified 
serum RNA with a fixed volume was reverse transcribed 
using the TaqMan miRNA Reverse Transcription Kit and 
miRNA-specific stem-loop primers (Applied Biosystems, 
CA, USA) using an Eppendorf Thermal Cycler at 16°C for 
30 min, 42°C for 30 min, and 85°C for 5 min. The 6 μL 
of PCR reaction included 2 μL of diluted (1:10) reverse 
Oncotarget9www.impactjournals.com/oncotarget
transcription product, 3 μL of TaqMan 2X Universal 
PCR Master Mix, 0.3 μL of 20X TaqMan miRNA Probe 
Assay, and 0.7 μL of nuclease-free water. Real-time PCR 
was carried out on a ViiA 7 real-time PCR platform (Life 
Technologies) at 95 °C for 10 min, followed by 40 cycles 
of 95°C for 15 sec and 60°C for 1 min in a 384-well 
plate. All samples were run in duplicate. To ensure the 
reliability of experimental data, several negative controls, 
including no-template, no reverse-transcriptase, and no-
reaction buffer negative controls were added in the reverse 
transcription phase, and no-template, water-template, no 
polymerase, and no-reaction buffer negative controls were 
added in the PCR phase. The C. elegans miRNAs were 
used as positive controls [17]. The raw cycle threshold 
(Ct) value for each miRNA was normalized to the raw 
Ct value for spike-in C. elegans miRNAs obtained from 
each individual sample to eliminate potential variations 
introduced from the processes of RNA isolation and 
quantification [49].
Identification of differentially expressed miRNAs
Using Relative Quantification Software version 
2.3 (Life Technologies), the Ct values of miRNAs were 
determined using default threshold settings and the mean 
Ct was calculated. Data points that generated duplicated 
Ct values with more than one cycle variance were 
repeated. The delta Ct values were defined as the mean 
Ct value for a specific miRNA in an individual sample 
minus the averaged Ct value of spike-in synthetic C. 
elegans miRNAs for the same sample. Those miRNAs 
with ≥ 50% missing values (miR-98 and miR-338-3p) 
were excluded from further analysis. The delta Ct values 
were then log2 transformed and median centered by arrays 
using the adjusting data function of Cluster 3.0 software 
for cluster analysis (Stanford University). The significant 
differentially expressed miRNAs between HBV patients 
with and without HCC development were identified using 
SAM (version 4.0) [50]. SAM gives estimates of the false 
discovery rate (FDR), which is the proportion of genes 
likely to have been false positively identified by chance 
as being significant. The effect of multiple comparisons 
was controlled through FDR [51]. In our study, FDR 
was estimated with 5000 permutations (the maximum 
permissible number), with a threshold of ≤ 5% as being 
significant. Unsupervised hierarchical clustering using 
Euclidean distance and Centroid linkage in Cluster 3.0 was 
carried out to cluster variables into groups based on their 
similarity, and the results were visualized in a dendrogram 
by Java TreeView version1.1.6r4 [52].
miRNAs target prediction, pathway analysis, 
and network analysis
To explore the molecular functions of the significant 
miRNAs identified in our study, the potential target 
genes of these miRNAs were in silico predicted using 
four miRNA target prediction algorithms, including the 
TargetScan (http://www.targetscan.org), miRanda (http://
www.microrna.org/microrna/home.do), miRDB (http://
mirdb.org/miRDB), and PicTar (http://pictar.mdc-berlin.
de). We compiled the target genes that are predicted by 
all of the four databases, and explored their functional 
interrelatedness using the IPA software (Ingenuity 
Systems, Redwood City, CA). Top-ranked pathways that 
are implicated in miRNA-mediated HCC development 
were determined based on the incidence of predicted 
miRNA targets in a list of canonical pathways provided by 
IPA. This software also generated the top-ranked networks 
comprising of the predicted miRNA targets. The biological 
functions associated with these networks were curated 
through Gene Ontology [53]. Fisher’s exact test was used 
to calculate a P value determining the significance of the 
probability of the association between the genes in the 
dataset and the canonical pathways.
Statistical analyses
The clinical outcome analyzed in this study was 
the diagnosis of HCC. Time to the event was defined as 
the time from blood sample taken to the date of HCC 
diagnosis (for HCC patients), or last follow-up (for 
cancer-free HBV patients). All patients included in this 
study had been followed for at least 1 year and had not 
developed HCC within this 1-year follow-up (1-year 
exclusion window). To minimize the confounding effect 
of any patient who had undiagnosed HCC at baseline 
sample collection, we further restricted the analyses to 
a sub-cohort of patients with a 2-year exclusion window 
(followed for at least 2 years and had not developed HCC 
within these 2 years). Chi-square testing was used to 
compare the distributions of host characteristics in HBV 
patients who developed HCC and those who did not. To 
analyze the significant miRNAs as a panel, we assigned 
each patient a risk score that was developed based on a 
linear combination of the expression levels of the miRNAs 
multiplied by the SAM d-values, and then used the median 
risk score in cancer-free HBV patients as the cutoff point 
[44, 49, 54]. The cumulative incidence of HCC by follow-
up years was plotted using the Nelson-Aalen method, and 
the difference between the patients with high- and low-risk 
scores was compared using log-rank test. The association 
between miRNAs risk scores and HCC risk was estimated 
using HR with 95% CI calculated by a univariate and 
multivariate Cox proportional hazards model, adjusting 
for age, gender, smoking status, drinking status, family 
history of cancer, cirrhosis status, and AFP values. 
Discrimination accuracy for predicting the development 
of HCC within 5 years after the baseline blood sample 
collection using miRNAs risk scores (alone or combined 
with baseline AFP) was evaluated by the C-index. The 
differences in discrimination accuracy between different 
Oncotarget10www.impactjournals.com/oncotarget
models (miRNA scores with and without AFP) were 
assessed by 10,000 bootstrap resampling. SAS (version 
9.3, SAS Institute, Cary, NC) and STATA (version 11.0, 
STATA Corp., College station, TX) software packages 
were used for these analyses. All P values were 2-sided, 
with a P value of less than 0.05 considered the threshold 
for statistical significance.
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